Qiagen : Q3 results ahead of guidance and estimates – 2023 guidance confirmed but looks challenging
>Q3 results beat guidance and consensus - Qiagen’s FX adjusted net sales came in at $ 470m, $ 5m above the company’s guidance and consensus and basically in line with our estimates of €472m. Compared with Q3 2022, nets sales were down c. 6%, as sales of Covid product groups declined by 59% to $ 34m. The Q3 2023 adjusted EBIT margin was 26.5% (28.7% in Q3 2022) slightly below our estimates of 26.9% and consensus of 27.1%. Adjusted EPS of $ 0.50 were down by nearly 6%, ...Qiagen is provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. Co.'s sample technologies process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software interprets data. Automation solutions unite these together in molecular testing workflows. Co. provides these workflows to four classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Co. markets its products in more than 130 countries.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.